Lipolysis

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, May 10, 2022
Drug development, MGH, Interim, Safety, Degenerative disease, MB, Risk, New Enterprise Associates, Massachusetts General Hospital, GH, SEC, CEO, Pediatrics, Fatty liver disease, BS, NASDAQ, Company, Private Securities Litigation Reform Act, Fibrosis, Patient, Clinical trial, FDA, Hypopituitarism, Inflammation, Disease, NASH, NEA, Optimism, PD, Growth hormone, Research, Liver disease, Growth hormone secretagogue receptor, MD, LUMO, Quarter, Transgender hormone therapy, Orphan, GLOBE, UCB, Review, Webcast, Therapy, Data, Lipolysis, Non-alcoholic fatty liver disease, PEM, Hormone Research in Paediatrics, Growth hormone secretagogue, Fine chemical, Pharmaceutical industry, Dietary supplement, Online gambling, Public relations, Lumos, NAFLD, EU

AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended March 31, 2022 and clinical development updates.

Key Points: 
  • AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended March 31, 2022 and clinical development updates.
  • Financial Results for the Quarter Ended March 31, 2022
    Cash Position Lumos Pharma ended the quarter on March 31, 2022 with cash and cash equivalents totaling $86.8 million compared to $94.8 million on December 31, 2021.
  • Lumos Pharma ended the first quarter 2022 with 8,358,625 shares outstanding.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Retrieved on: 
Thursday, May 5, 2022
Drug development, Assistant professor, Prevalence, Fatty liver disease, Degenerative disease, Human, Risk, Hospital, Administration, New Enterprise Associates, Massachusetts General Hospital, GH, SEC, CEO, Veni, vidi, vici, Woman, NASDAQ, Bilirubin, Private Securities Litigation Reform Act, Patient, Fibrosis, FDA, Letter, Incidence, Uncertainty, Pandemic, Disease, NASH, Nass, Liver, Hypothalamus, Body composition, NEA, Optimism, Population, IND, Physician, Growth hormone, Liver disease, Non-alcoholic fatty liver disease, MD, Growth, Man, LUMO, Department, Orphan, GLOBE, UCB, Therapy, Lipolysis, Adult, Biological activity, Harvard Medical School, Pharmaceutical industry, Dietary supplement, Public relations, Lumos, NAFLD, EU, Science

Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.

Key Points: 
  • Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.
  • Nonalcoholic fatty liver disease is estimated to be prevalent in approximately 25% of adults worldwide.
  • This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.
  • The trial will evaluate a dose of 25 mg/day of LUM-201 in 10 men and women with NAFLD.

Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX

Retrieved on: 
Thursday, April 28, 2022
Hair, Securities Exchange Act of 1934, Body mass index, GLOBE, COVID-19, Lipolysis, Efficiency, Food, Technology, Growth, Securities Act of 1933, Company, FUE, Annual report, Magnetic field, Communication, Abdomen, NASDAQ, EMS, ARTAS, Cellulite, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Scalp, Human, Medical device, Risk management

TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device (BlissMAX) with an expanded indication for use in new areas of the body and an increase in RF energy output.

Key Points: 
  • TORONTO, April 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device (BlissMAX) with an expanded indication for use in new areas of the body and an increase in RF energy output.
  • In addition to these technologies, BlissMAX also features the Companys FlexMAX EMS applicators, designed for muscle conditioning to stimulate healthy muscles.
  • Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD.

Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX for Non-Invasive Lipolysis of the Abdomen and Flanks, Cellulite Reduction and Muscle Conditioning

Retrieved on: 
Tuesday, January 18, 2022
Securities Exchange Act of 1934, Abdomen, ARTAS, Cellulite, Scalp, SEC, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Growth, NASDAQ, GLOBE, BMI, FUE, Industry, Company, Hair, Lipolysis, Food, Communication, EMS, FDA, Securities Act of 1933, Magnetic field, Annual report, Risk management

BlissMAX is a medical aesthetic platform that offers a comprehensive solution for fat reduction, cellulite reduction and muscle conditioning with three technologies in one platform.

Key Points: 
  • BlissMAX is a medical aesthetic platform that offers a comprehensive solution for fat reduction, cellulite reduction and muscle conditioning with three technologies in one platform.
  • In addition to these technologies, BlissMAX also features the Companys FlexMAX EMS applicators, designed for muscle conditioning to stimulate healthy muscles.
  • We are very pleased to receive FDA 510(k) clearance for BlissMAX, the next generation of our Venus Bliss system, earlier than anticipated, said Domenic Serafino, Chief Executive Officer of Venus Concept.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Freedom, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD.

Global Body Contouring Devices Market Industry Analysis and Forecasts 2021-2027, Featuring Allergan, Cutera, InMode, Sciton, Lumenis and Lutronic - ResearchAndMarkets.com

Retrieved on: 
Friday, December 3, 2021
Fitness & Nutrition, Health, Medical Devices, People, Skin, Technology, Elective surgery, Scar, Face, CAGR, Forecasting, Medical tourism, Abdomen, Plastic, Deoxycholic acid, Injection, Application, Weight loss, Neck, Breast, Obesity, Risk, Human, Society, FDA, American Society of Plastic Surgeons, ASPS, Growth, Lipolysis, Cosmetics

The Global Body Contouring Devices Market size is expected to reach $8.4 billion by 2027, rising at a market growth of 16.1% CAGR during the forecast period.

Key Points: 
  • The Global Body Contouring Devices Market size is expected to reach $8.4 billion by 2027, rising at a market growth of 16.1% CAGR during the forecast period.
  • Furthermore, the market growth is further driven by the global surge in aesthetic consciousness and body contouring improvements like liposuction, skin tightening, and excess skin removal.
  • The increasing number of obese people is among the key factors supporting the growth of the body contouring devices market.
  • The Asia Pacific market is projected to exhibit the highest growth rate in the body contouring devices market over the forecast period.

D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, Clinical trial, Weight loss, Achievement, Fatty liver disease, Solution, Patient, Lists of diseases, NAFLD, NASH, Diabetes, CEO, Obesity, Neurodegeneration, D&D, D, Glucagon-like peptide-1 receptor, Lipolysis, Weight, Disorder, Pharmaceutical industry, DD01, D&D Pharmatech, Salubris, DD01, D&D PHARMATECH, SALUBRIS

D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced that Shenzhen Salubris Pharmaceuticals has acquired the rights to develop and commercialize DD01 in mainland China.

Key Points: 
  • D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced that Shenzhen Salubris Pharmaceuticals has acquired the rights to develop and commercialize DD01 in mainland China.
  • DD01 is a glucagon-like peptide-1 receptor / glucagon receptor (GLP-1R/GCGR) dual agonist for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and diabetes.
  • DD01 is currently being investigated in a phase 1 clinical trial which is being conducted in the U.S.
  • This licensing agreement reflects the potential of DD01 for the treatment of obesity, NASH and diabetes, said Yoo-Seok Hong, Chief Executive Officer of D&D Pharmatech.

Lumen Health Tech Reveals 60% of Employed Users Lost Weight During the Pandemic by Measuring Their Metabolism Daily

Retrieved on: 
Tuesday, August 17, 2021
Health, Medical Devices, Other Health, Fitness & Nutrition, Managed Care, General Health, Biotechnology, Degenerative disease, Doctor of Philosophy, Ageing, Privacy, Knowledge, Estradiol, App Store (iOS/iPadOS), Pulse, Health, Metabolism, Lipolysis, Inflammation, Multimedia, Adult, Ironman, Physiology, Google Play, San Francisco State University, Woman, API, Technology, Virgin Group, Mobile phone, Electric light, Medical imaging, Health insurance, Medical device

Enter Lumen- the device and health technology focused on improving your metabolism, the key to sustainable health.

Key Points: 
  • Enter Lumen- the device and health technology focused on improving your metabolism, the key to sustainable health.
  • On average, Lumen users that measure their metabolism for 12 months improve their metabolism by 40% and lose 2% of their body weight monthly.
  • Prior to using Lumen, users reported feeling out of control of their health, with 40% saying their metabolism had declined.
  • Lastly, employed Lumen users mostly agreed that Lumen would be of great value for employees in a corporate offering setting.

Smooth Body Contour Receives "Top Medical Spa East Coast" and Lucie T Alexandre wins "Top Women Business Owners" in the Aesthetic Everything® Aesthetic and Cosmetic Medicine Awards 2021

Retrieved on: 
Friday, February 19, 2021
Medicine, Medical specialties, Clinical medicine, Medical terminology, Minimally-invasive surgery, Cosmetic surgery, Invasive procedure, Lipolysis, Minimally invasive procedure, Surgery

ORLANDO, Fla., Feb. 19, 2021 /PRNewswire/ --Smooth Body Contour Receives "Top Medical Spa East Coast", "Top Non-Surgical Procedures Med Spa" "Top Minimally Invasive Procedures Med Spa" and "Top Training Centers" and Lucie T. Alexandre wins "Top Women Business Owners" and "Top Women Aesthetic Trainers" in the Aesthetic Everything Aesthetic and Cosmetic Medicine Awards 2021.

Key Points: 
  • ORLANDO, Fla., Feb. 19, 2021 /PRNewswire/ --Smooth Body Contour Receives "Top Medical Spa East Coast", "Top Non-Surgical Procedures Med Spa" "Top Minimally Invasive Procedures Med Spa" and "Top Training Centers" and Lucie T. Alexandre wins "Top Women Business Owners" and "Top Women Aesthetic Trainers" in the Aesthetic Everything Aesthetic and Cosmetic Medicine Awards 2021.
  • The concept behind the company is a culmination of lifelong experiences with both women and men who struggle with maintaining their shape and figure.
  • We stand by our products and slogan in order to help women and men to contour their body the way they want.
  • Smooth Body Contours offers minimally invasive procedures such as Laser Lipo, cryolipolysis, Aqualyx (liquid Lipo), and our patient's favorite Art Lipo.

Non-invasive Fat Reduction Market Size Worth $1.6 billion by 2027: Grand View Research, Inc.

Retrieved on: 
Monday, June 22, 2020
Nature, Medicine, Natural environment, Hepatology, Lipolysis, Metabolism, Invasive species, Fat removal procedures

SAN FRANCISCO, June 22, 2020 /PRNewswire/ -- The global non-invasive fat reduction market size is expected to reach USD 1.6 billion by 2027, expanding at a CAGR of 16.4%, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 22, 2020 /PRNewswire/ -- The global non-invasive fat reduction market size is expected to reach USD 1.6 billion by 2027, expanding at a CAGR of 16.4%, according to a new report by Grand View Research, Inc.
  • Treatments like Cryolipolysis, low level lasers, and ultrasound are the most commonly used methods for noninvasive fat reduction procedures.
  • Rising contribution of market players is playing a prominent role in promoting such procedures.
  • Grand View Research has segmented the global non-invasive fat reduction market on the basis of technology type, end use, and region:
    Non-invasive Fat Reduction Technology Type Outlook (Revenue, USD Million, 2016 - 2027)

Non-invasive Fat Reduction Market Size Worth $1.6 billion by 2027: Grand View Research, Inc.

Retrieved on: 
Monday, June 22, 2020
Nature, Medicine, Natural environment, Hepatology, Lipolysis, Metabolism, Invasive species, Fat removal procedures

SAN FRANCISCO, June 22, 2020 /PRNewswire/ -- The global non-invasive fat reduction market size is expected to reach USD 1.6 billion by 2027, expanding at a CAGR of 16.4%, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 22, 2020 /PRNewswire/ -- The global non-invasive fat reduction market size is expected to reach USD 1.6 billion by 2027, expanding at a CAGR of 16.4%, according to a new report by Grand View Research, Inc.
  • Treatments like Cryolipolysis, low level lasers, and ultrasound are the most commonly used methods for noninvasive fat reduction procedures.
  • Rising contribution of market players is playing a prominent role in promoting such procedures.
  • Grand View Research has segmented the global non-invasive fat reduction market on the basis of technology type, end use, and region:
    Non-invasive Fat Reduction Technology Type Outlook (Revenue, USD Million, 2016 - 2027)